StockData

Alnylam Pharmaceuticals vs Royalty Pharma

ALNY and RPRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALNY and RPRX compare

Royalty Pharma is the larger company, worth 1.9 times as much as Alnylam Pharmaceuticals ($39.5B against $21.0B).

On earnings, Alnylam Pharmaceuticals is cheaper: it trades at 8.1× trailing earnings, against 39.0× for Royalty Pharma.

Alnylam Pharmaceuticals grew revenue faster over the last twelve months (56.2% versus 10.0% for Royalty Pharma).

Alnylam Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 52.8% compared with 32.1% at Royalty Pharma.

Royalty Pharma pays a dividend yielding 1.4%; Alnylam Pharmaceuticals does not pay one.

Alnylam Pharmaceuticals scores higher on the StockData Score (10 against 8 for Royalty Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALNYRPRX
Size and price
Market cap$21.0B$39.5B
Share price$156.50$68.68
Change, 1 year−65.2%75.4%
Change, 5 years−17.0%64.0%
Beta (5Y)0.920.04
Employees2,500100
StockData Score
Total score10 (better)8
Valuation score3 (better)0
Growth score22
Performance score3 (better)2
Health score22
Dividend score02 (better)
Valuation
P/E8.1× (better)39.0×
P/S4.2× (better)15.6×
P/B5.8×–
EV/EBITDA16.8× (better)33.5×
P/FCF26.0×–
PEG–0.24
FCF yield3.8%–
Fair value$296.91$45.76
Margin of safety47.3% (better)−50.1%
Growth
Revenue growth (TTM)56.2% (better)10.0%
Revenue growth, 5Y average49.8% (better)2.3%
Net income growth (TTM)2137% (better)−20.4%
EPS growth (TTM)2308% (better)−19.3%
EPS growth, 5Y average–6.2%
Profitability
Gross margin77.4%–
Operating margin19.5%59.6% (better)
Net margin52.8% (better)32.1%
FCF margin16.1%–
Return on equity127%–
Financial health
Net debt / EBITDA–5.37
Interest coverage3.2×4.2× (better)
Current ratio2.482.80 (better)
Altman Z-score3.62 (better)2.98
Piotroski F-score6 (better)5
Dividends and buybacks
Dividend yield–1.4%
Buyback yield–0.81%
Shareholder yield0.00%2.2% (better)
Ownership
Held by institutions99.7%63.8%
Held by insiders0.49%22.6%
Insider net buying, 12 months−$26.3M (better)−$82.2M
Superinvestors holding–2
Short interest, % of float4.1%2.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.